Extension of use of nicotinamide riboside chloride as a novel food pursuant to Regulation (EU) 2015/2283

EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), Dominique Turck, Torsten Bohn, Jacqueline Castenmiller, Stefaan De Henauw, Karen Ildico Hirsch-Ernst, Alexandre Maciuk, Inge Mangelsdorf, Harry J McArdle, Androniki Naska, Carmen Pelaez, Kristina Pentieva, Alfonso Siani, Frank Thies, Sophia Tsabouri, Marco Vinceti, Francesco Cubadda, Thomas Frenzel, Marina Heinonen, Miguel Prieto Maradona, Rosangela Marchelli, Monika Neuhäuser-Berthold, Morten Poulsen, Josef Rudolf Schlatter, Henk van Loveren, Océane Albert, Agnès de Sesmaisons Lecarré, Helle Katrine Knutsen, EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), Dominique Turck, Torsten Bohn, Jacqueline Castenmiller, Stefaan De Henauw, Karen Ildico Hirsch-Ernst, Alexandre Maciuk, Inge Mangelsdorf, Harry J McArdle, Androniki Naska, Carmen Pelaez, Kristina Pentieva, Alfonso Siani, Frank Thies, Sophia Tsabouri, Marco Vinceti, Francesco Cubadda, Thomas Frenzel, Marina Heinonen, Miguel Prieto Maradona, Rosangela Marchelli, Monika Neuhäuser-Berthold, Morten Poulsen, Josef Rudolf Schlatter, Henk van Loveren, Océane Albert, Agnès de Sesmaisons Lecarré, Helle Katrine Knutsen

Abstract

Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on the safety of an extension of use of the novel food (NF) nicotinamide riboside chloride (NRC) pursuant to Regulation (EU) 2015/2283. The assessment addresses the use of NRC in 'meal replacement products' and 'nutritional drink mixes' at levels up to 300 mg/day for the general population, and in food for special medical purposes (FSMP) and total diet replacement for weight control (TDRWC) (as per Regulation (EU) No 609/2013) at levels up to 500 mg/day in adults. Benchmark dose modelling was carried out on data from the 90-day oral toxicity studies in rats relevant to the safety assessment. Considering the lack of tolerable upper intake level (UL) for nicotinamide in infants and the narrow margin of exposure between the estimated intake in infants and the lower confidence bound of the benchmark doses (BMDL 05) estimated by the models, the Panel concludes that the safety of the NF has not been established for use in 'meal replacement products' and 'nutritional drink mixes' under the proposed conditions of use. For FSMP and TDRWC, the proposed maximum use level corresponds to an intake of 210 mg nicotinamide per day, which is below the current UL for nicotinamide of 900 mg/day for adults. The Panel considers that the NF is as safe as pure nicotinamide for use in FSMP and TDRWC. The Panel, however, notes experimental data which indicate several pathways by which intakes of nicotinamide (or its precursors), at levels that are substantially higher than the physiological requirement, might cause adverse effects. The Panel considers that further investigations are required and that a re-evaluation of the UL for nicotinamide may be warranted.

Keywords: extension of use; niacin; nicotinamide; nicotinamide riboside chloride; novel food; nutrient source.

© 2021 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf of European Food Safety Authority.

Figures

Figure D.1
Figure D.1
Visualisation of the individual BMD model curves
Figure D.2
Figure D.2
Visualisation of bootstrap curves based on BMD model averaging
Figure D.3
Figure D.3
Visualisation of the individual BMD model curves
Figure D.4
Figure D.4
Visualisation of bootstrap curves based on BMD model averaging
Figure D.5
Figure D.5
Visualisation of the individual BMD model curves
Figure D.6
Figure D.6
Visualisation of bootstrap curves based on BMD model averaging
Figure D.7
Figure D.7
Visualisation of the individual BMD model curves
Figure D.8
Figure D.8
Visualisation of bootstrap curves based on BMD model averaging

References

    1. Airhart SE, Shireman LM, Risler LJ, Anderson GD, Nagana Gowda GA, Raftery D, Tian R, Shen DD and O'Brien KD, 2017. An open‐label, non‐randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy volunteers. PLoS One, 12, e0186459. 10.1371/journal.pone.0186459
    1. Al‐Gayyar MMH, Bagalagel A, Noor AO, Almasri DM and Diri R, 2019. The therapeutic effects of nicotinamide in hepatocellular carcinoma through blocking IGF‐1 and effecting the balance between Nrf2 and PKB. Biomedicine & Pharmacotherapy, 112. 10.1016/j.biopha.2019.108653
    1. Bartleman AP, Jacobs R and Kirkland JB, 2008. Niacin supplementation decreases the incidence of alkylation‐induced nonlymphocytic leukemia in Long‐Evans rats. Nutrition and Cancer, 60, 251–258. 10.1080/01635580701649628
    1. Bhoite P and Jayachandra K (Syngene International Limited), 2014. Single Dose Oral Toxicity Study of Niagen in Sprague Dawley Rats. Bangalore, India. 60 pp.
    1. Bhoite P, Jayachandra K and Suman M (Syngene International Limited), 2015. Comparative 90‐Day Oral Toxicity Study of Niagen and Nicotinamide in Sprague Dawley Rats. Bangalore, India. 291 pp.
    1. Braidy N and Liu Y, 2020. Can nicotinamide riboside protect against cognitive impairment? Current Opinion in Clinical Nutrition and Metabolic Care, 23, 413–420. 10.1097/MCO.0000000000000691
    1. Conze DB, Crespo‐Barreto J and Kruger CL, 2016. Safety assessment of nicotinamide riboside, a form of vitamin B3. Human and Experimental Toxicology, 35, 1149–1160. 10.1177/0960327115626254
    1. Conze D, Brenner C and Kruger CL, 2019. Safety and metabolism of long‐term administration of NIAGEN (nicotinamide riboside chloride) in a randomized, double‐blind, placebo‐controlled clinical trial of healthy overweight adults. Scientific Reports, 9, 9772. 10.1038/s41598-019-46120-z
    1. Dellinger RW, Santos SR, Morris M, Evans M, Alminana D, Guarente L and Marcotulli E, 2017. Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD(+) levels in humans safely and sustainably: a randomized, double‐blind, placebo‐controlled study. NPJ Aging and Mechanisms of Disease, 3, 17. 10.1038/s41514-017-0016-9
    1. Demarest TG, Babbar M, Okur MN, Dan X, Croteau DL, Fakouri NB, Mattson MP and Bohr VA, 2019. NAD+ metabolism in aging and cancer. Annual Review of Cancer Biology, 3, 105–130. 10.1146/annurev-cancerbio-030518-055905
    1. Dibusz K and Vejvodova P, 2020. Systematic literature search to assist EFSA in the preparatory work for the safety assessment of Novel Food applications and Traditional Food notifications. EFSA Supporting Publications, 17, 1774E. 10.2903/sp.efsa.2019.EN-1774
    1. Dollerup OL, Christensen B, Svart M, Schmidt MS, Sulek K, Ringgaard S, Stodkilde‐Jorgensen H, Moller N, Brenner C, Treebak JT and Jessen N, 2018. A randomized placebo‐controlled clinical trial of nicotinamide riboside in obese men: safety, insulin‐sensitivity, and lipid‐mobilizing effects. American Journal of Clinical Nutrition, 108, 343–353. 10.1093/ajcn/nqy132
    1. EFSA (European Food Safety Authority), 2004. Opinion of the Scientific Panel on food additives, flavourings, processing aids and materials in contact with food (AFC) on a request from the Commission related to Furfural and Furfural Diethylacetal. EFSA Journal 2004;2:67, 26 pp.
    1. EFSA (European Food Safety Authority) , 2006. Opinion of the Scientific Committee on Food on the tolerable upper intake level of nicotinic acid and nicotinamide (Niacin): expressed on 17 April 2002. In: SCF (Scientific Committee on Food) and EFSA NDA Panel (Scientific Panel on Dietetic Products, Nutrition and Allergies). Tolerable upper intake levels for vitamins and minerals. EFSA, s.l. 121–134. pp. Available online:
    1. EFSA ANS Panel (EFSA Panel on Food Additives and Nutrient Sources added to Food), Younes M, Aggett P, Aguilar F, Crebelli R, Dusemund B, Filipicč M, Frutos MJ, Galtier P, Gundert‐Remy U, Kuhnle GG, Lambré C, Leblanc J‐C, Lillegaard IT, Moldeus P, Mortensen A, Oskarsson A, Stankovic I, Waalkens‐Berendsen I, Woutersen RA, Wright M, Di Domenico A, Fairweather‐Tait S, McArdle H, Smeraldi C and Gott D, 2018. Guidance on safety evaluation of sources of nutrients and bioavailability of nutrient from the sources. EFSA Journal 2018;16:5294. 10.2903/j.efsa.2018.5294
    1. EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2014. Scientific opinion on dietary reference values for niacin. EFSA Journal 2014;12(7):3759, 42 pp.
    1. EFSA NDA Panel , (EFSA Panel on Dietetic Products, Nutrition and Allergies), Turck D, Bresson J‐L, Burlingame B, Dean T, Fairweather‐Tait S, Heinonen M, Hirsch‐Ernst KI, Mangelsdorf I, McArdle H, Naska A, Neuhäuser‐Berthold M, Nowicka G, Pentieva K, Sanz Y, Siani A, Sjödin A, Stern M, Tomé D, Vinceti M, Willatts P, Engel K‐H, Marchelli R, Pöting A, Poulsen M, Salminen S, Schlatter J, Arcella D, Gelbmann W, de Sesmaisons‐Lecarré A, Verhagen H and van Loveren H, 2016. Guidance on the preparation and presentation of an application for authorisation of a novel food in the context of Regulation (EU) 2015/2283. EFSA Journal 2016;14(11):e04594, 24 pp. 10.2903/j.efsa.2016.4594
    1. EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), Turck D, Bresson J‐L, Burlingame B, Dean T, Fairweather‐Tait S, Heinonen M, Hirsch‐Ernst K, Mangelsdorf I, McArdle H, Naska A, Neuhäuser‐Berthold M, Nowicka G, Pentieva K, Sanz Y, Siani A, Sjödin A, Stern M, Tomé D, Vinceti M, Willatts P, Engel K‐H, Marchelli R, Pöting A, Poulsen M, Schlatter J, Germini A and Van Loveren H, 2018. Scientific opinion on safety of d‐ribose as a novel food pursuant to Regulation (EU) 2015/2283. EFSA Journal 2018;16(5):5265, 75 pp. 10.2903/j.efsa.2018.5265
    1. EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), Turck D, Castenmiller J, de Henauw S, Hirsch‐Ernst KI, Kearney J, Maciuk A, Mangelsdorf I, McArdle HJ, Naska A, Pelaez C, Pentieva K, Siani A, Thies F, Tsabouri S, Vinceti M, Cubadda F, Engel KH, Frenzel T, Heinonen M, Marchelli R, Neuhauser‐Berthold M, Poting A, Poulsen M, Sanz Y, Schlatter JR, van Loveren Agnes de Sesmaisons‐Lecarre H, Germini A and Knutsen HK, 2019. Safety of nicotinamide riboside chloride as a novel food pursuant to Regulation (EU) 2015/2283 and bioavailability of nicotinamide from this source, in the context of Directive 2002/46/EC. EFSA Journal 2019;17(8):e05775, 45 pp. 10.2903/j.efsa.2019.5775
    1. EFSA Scientific Committee , 2012. Guidance on selected default values to be used by the EFSA Scientific Committee, Scientific Panels and Units in the absence of actual measured data. EFSA Journal 2012;10(3):2579, 32 pp. 10.2903/j.efsa.2012.2579
    1. EFSA Scientific Committee , Hardy A, Benford D, Halldorsson T, Jeger MJ, Knutsen KH, More S, Mortensen A, Naegeli H, Noteborn H, Ockleford C, Ricci A, Rychen G, Silano V, Solecki R, Turck D, Aerts M, Bodin L, Davis A, Edler L, Gundert‐Remy U, Sand S, Slob W, Bottex B, Abrahantes JC, Marques DC, Kass G and Schlatter JR, 2017. Update: guidance on the use of the benchmark dose approach in risk assessment. EFSA Journal 2017;15(1):4658, 41 pp. 10.2903/j.efsa.2017.4658
    1. French FA, 1977. The influence of nutritional factors on pulmonary adenomas in mice. Advances in Experimental Medicine and Biology, 91, 281–292. 10.1007/978-1-4684-0796-9_19
    1. Ganiger S (Advinus Therapeutics Limited), 2016. Nicotinamide Riboside Chloride: One Generation Reproduction Toxicity Study Through Diet in Sprague‐Dawley Rats. Bangalore, India. 313 pp.
    1. Geetha Rao G (Advinus Therapeutics Limited), 2016. Nicotinamide Riboside Chloride: Embryo‐Fetal Developmental Toxicity Study in Sprague Dawley Rats by Oral Route. Bangalore, India. 319 pp.
    1. Gensler HL, 1997. Prevention of photoimmunosuppression and photocarcinogenesis by topical nicotinamide. Nutrition and Cancer, 29, 157–162. 10.1080/01635589709514618
    1. Gensler HL, Williams T, Huang AC and Jacobson EL, 1999. Oral niacin prevents photocarcinogenesis and photoimmunosuppression in mice. Nutrition and Cancer, 34, 36–41. 10.1207/S15327914NC340105
    1. Gotoh H, Nomura T, Nakajima H, Hasegawa C and Sakamoto Y, 1988. Inhibiting effects of nicotinamide on urethane‐induced malformations and tumors in mice. Mutation Research, 199, 55–63. 10.1016/0027-5107(88)90230-8
    1. Gotoh H, Nomura T and Hasewaga C, 1993. Growth‐inhibition of transplanted murine‐breast cancer by nicotinamide in C3H/HEJ mice. Cancer Research Therapy & Control, 3, 121–126.
    1. Horsman MR, Khalil AA, Chaplin DJ and Overgaard J, 1995. The ability of nicotinamide to inhibit the growth of a C3H mouse mammary carcinoma. Acta Oncologica, 34, 443–446. 10.3109/02841869509094006
    1. Hwang ES and Song SB, 2020. Possible adverse effects of high‐dose nicotinamide: mechanisms and safety assessment. Biomolecules, 10, 687. 10.3390/biom10050687
    1. Kamath G (Syngene International Limited), 2015. Bacterial Reverse Mutation Test with Niagen. Bangalore, India. 71 pp.
    1. Kamath G (Syngene International Limited), 2016. In Vitro Mammalian Chromosome Aberration Test Using Human Peripheral Blood Lymphocyte with Niagen. Bangalore, India. 69 pp.
    1. Kato T, Berger SJ, Carter JA and Lowry OH, 1973. An enzymatic cycling method for nicotinamide‐adenine dinucleotide with malic and alcohol dehydrogenases. Analytical Biochemistry, 53, 86–97. 10.1016/0003-2697(73)90409-0
    1. Kazgan N, Metukuri MR, Purushotham A, Lu J, Rao A, Lee S, Pratt‐Hyatt M, Lickteig A, Csanaky IL, Zhao Y, Dawson PA and Li X, 2014. Intestine‐specific deletion of SIRT1 in mice impairs DCoH2‐HNF‐1alpha‐FXR signaling and alters systemic bile acid homeostasis. Gastroenterology, 146, 1006–1016. 10.1053/j.gastro.2013.12.029
    1. Kim SK, Yun SJ, Kim J, Lee OJ, Bae SC and Kim WJ, 2011a. Identification of gene expression signature modulated by nicotinamide in a mouse bladder cancer model. PLoS One, 6, e26131, 10.1371/journal.pone.0026131
    1. Kim WJ, Lee JW, Quan C, Youn HJ, Kim HM and Bae SC, 2011b. Nicotinamide inhibits growth of carcinogen induced mouse bladder tumor and human bladder tumor xenograft through up‐regulation of RUNX3 and p300. Journal of Urology, 185, 2366–2375. 10.1016/j.juro.2011.02.017
    1. Knip M, Douek IF, Moore WP, Gillmor HA, McLean AE, Bingley PJ and Gale EA; and European Nicotinamide Diabetes Intervention Trial G , 2000. Safety of high‐dose nicotinamide: a review. Diabetologia, 43, 1337–1345.
    1. Ludwig A, Dietel M, Schafer G, Muller K and Hilz H, 1990. Nicotinamide and nicotinamide analogues as antitumor promoters in mouse skin. Cancer Research, 50, 2470–2475.
    1. Maki KC, Dicklin MR, Sanders LM, Palacios OM, Wilcox M, and Maki CE (MB Clinical Research), 2020. Safety and Metabolic Effects of Nicotinamide Riboside in a Randomized, Double‐blind, Crossover, Placebo‐controlled Trial of Men and Women ≥ 55 Years of Age. Boca Raton, Florida, United States. Unpublished study report, 25 pp.
    1. Marinescu AG, Chen J, Holmes HE, Guarente L, Mendes O, Morris M and Dellinger RW, 2020. Safety assessment of high‐purity, synthetic nicotinamide riboside (NR‐E) in a 90‐day repeated dose oral toxicity study, with a 28‐day recovery arm. International Journal of Toxicology, 39, 307–320. 10.1177/1091581820927406
    1. Martens C (The Integrative Physiology of Aging Laboratory, University of Colorado Boulder), 2017. NIAGEN® Supplementation for Improving Physical and Metabolic Function in Midlife and Older Adult Humans. Boulder, CO, USA, 28 pp.
    1. Martens CR, Denman BA, Mazzo MR, Armstrong ML, Reisdorph N, McQueen MB, Chonchol M and Seals DR, 2018. Chronic nicotinamide riboside supplementation is well‐tolerated and elevates NAD(+) in healthy middle‐aged and older adults. Nature Communications, 9, 1286. 10.1038/s41467-018-03421-7
    1. Nacarelli T, Lau L, Fukumoto T, Zundell J, Fatkhutdinov N, Wu S, Aird KM, Iwasaki O, Kossenkov AV, Schultz D, Noma KI, Baur JA, Schug Z, Tang HY, Speicher DW, David G and Zhang R, 2019. NAD(+) metabolism governs the proinflammatory senescence‐associated secretome. Nature Cell Biology, 21, 397–407. 10.1038/s41556-019-0287-4
    1. Olsson AR, Sheng Y, Pero RW, Chaplin DJ and Horsman MR, 1996. DNA damage and repair in tumour and non‐tumour tissues of mice induced by nicotinamide. British Journal of Cancer, 74, 368–373. 10.1038/bjc.1996.367
    1. Pamukcu AM, Milli U and Bryan GT, 1981. Protective effect of nicotinamide on bracken fern induced carcinogenicity in rats. Nutrition and Cancer, 3, 86–93. 10.1080/01635588109513707
    1. Pandey A (Syngene International Limited), 2016. In vivo Mammalian Erythrocyte Micronucleus Test in Rat with Niagen. Bangalore, India. 78 pp.
    1. Poljsak B, 2016. NAD+ in cancer prevention and treatment: pros and cons. Journal of Clinical & Experimental Oncology, 2016, 1–15.
    1. Pour PM and Lawson T, 1984. Modification of pancreatic carcinogenesis in the hamster model. XV. Preventive effect of nicotinamide. Journal of the National Cancer Institute, 73, 767–770.
    1. Rakieten N, Gordon BS, Beaty A, Cooney DA, Davis RD and Schein PS, 1971. Pancreatic islet cell tumors produced by the combined action of streptozotocin and nicotinamide. Proceedings of the Society for Experimental Biology and Medicine, 137, 280–283. 10.3181/00379727-137-35561
    1. Rakieten N, Gordon BS, Beaty A, Cooney DA, Schein PS and Dixon RL, 1976. Modification of renal tumorigenic effect of streptozotocin by nicotinamide: spontaneous reversibility of streptozotocin diabetes. Proceedings of the Society for Experimental Biology and Medicine, 151, 356–361. 10.3181/00379727-151-39209
    1. Remie CME, Roumans KHM, Moonen MPB, Connell NJ, Havekes B, Mevenkamp J, Lindeboom L, de Wit VHW, van de Weijer T, Aarts S, Lutgens E, Schomakers BV, Elfrink HL, Zapata‐Perez R, Houtkooper RH, Auwerx J, Hoeks J, Schrauwen‐Hinderling VB, Phielix E and Schrauwen P, 2020. Nicotinamide riboside supplementation alters body composition and skeletal muscle acetylcarnitine concentrations in healthy obese humans. American Journal of Clinical Nutrition, 112, 413–426. 10.1093/ajcn/nqaa072
    1. Roe FJ, 1962. Effect of massive doses of riboflavin, and other vitamins of the B group, on skin carcinogenesis in mice. British Journal of Cancer, 16, 252–257. 10.1038/bjc.1962.29
    1. Rosenberg MR, Novicki DL, Jirtle RL, Novotny A and Michalopoulos G, 1985. Promoting effect of nicotinamide on the development of renal tubular cell tumors in rats initiated with diethylnitrosamine. Cancer Research, 45, 809–814.
    1. SCF (Scientific Committee on Food), 2002. Opinion of the Scientific Committee on Food on the tolerable upper intake level of nicotinic acid and nicotinamide (niacin). 13 pp.
    1. Schacter G (KGK Science, Inc.), 2018. A Randomized, Double‐Blind, Placebo‐Controlled Parallel Study Investigating the Effects of NIAGEN® (Nicotinamide Riboside Chloride) on NIAGEN® Metabolites in Healthy Adults. London, Ontario, Canada. 313 pp.
    1. Schmahl D and Stackelberg S, 1968. [The effect of lactoflavin, nicotinic acid amide or dipyridamol on the cancerogenic action of diethylnitrosamine in rats]. Arzneimittel‐Forschung, 18, 318–320.
    1. Schoental R, 1977. The role of nicotinamide and of certain other modifying factors in diethylnitrosamine carcinogenesis: fusaria mycotoxins and “spontaneous” tumors in animals and man. Cancer, 40, 1833–1840. 10.1002/1097-0142(197710)40:4+<1833:aid-cncr2820400810>;2-l
    1. Sun WP, Li D, Lun YZ, Gong XJ, Sun SX, Guo M, Jing LX, Zhang LB, Xiao FC and Zhou SS, 2012. Excess nicotinamide inhibits methylation‐mediated degradation of catecholamines in normotensives and hypertensives. Hypertension Research, 35, 180–185. 10.1038/hr.2011.151
    1. Sun WP, Zhai MZ, Li D, Zhou Y, Chen NN, Guo M and Zhou SS, 2017. Comparison of the effects of nicotinic acid and nicotinamide degradation on plasma betaine and choline levels. Clinical Nutrition, 36, 1136–1142. 10.1016/j.clnu.2016.07.016
    1. Surjana D, Halliday GM and Damian DL, 2010. Role of nicotinamide in DNA damage, mutagenesis, and DNA repair. Journal of Nucleic Acids, 2010. 10.4061/2010/157591
    1. Thorsrud B (Experimur), 2017. Oral 7‐Day Dose Range Finding Toxicity Study in Juvenile Dogs with NIAGEN® . Chicago, IL, USA. 172 pp.
    1. Thorsrud B (Experimur), 2018. Oral 28‐Day Toxicity Study in Juvenile Dogs with NIAGEN® . Chicago, IL, USA. 388 pp.
    1. Tian YJ, Li D, Ma Q, Gu XY, Guo M, Lun YZ, Sun WP, Wang XY, Cao Y and Zhou SS, 2013. Excess nicotinamide increases plasma serotonin and histamine levels. Sheng Li Xue Bao: [Acta Physiologica Sinica], 65, 33–38.
    1. Tian YJ, Luo N, Chen NN, Lun YZ, Gu XY, Li Z, Ma Q and Zhou SS, 2014. Maternal nicotinamide supplementation causes global DNA hypomethylation, uracil hypo‐incorporation and gene expression changes in fetal rats. British Journal of Nutrition, 111, 1594–1601. 10.1017/S0007114513004054
    1. Toth B, 1983. Lack of carcinogenicity of nicotinamide and isonicotinamide following lifelong administration to mice. Oncology, 40, 72–75. 10.1159/000225695
    1. Trammell SA, Schmidt MS, Weidemann BJ, Redpath P, Jaksch F, Dellinger RW, Li Z, Abel ED, Migaud ME and Brenner C, 2016. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nature Communications, 7, 12948. 10.1038/ncomms12948
    1. Wilson D (KGK Synergize, Inc.), 2015. Randomized, Double‐blind, Cross‐over Study of the Pharmacokinetics of Three Dosages of Niagen™ in Healthy Subjects. London, Ontario, Canada. 212 pp.
    1. Zhang Y, Ma T and Zhang P, 2018. Efficacy and safety of nicotinamide on phosphorus metabolism in hemodialysis patients: a systematic review and meta‐analysis. Medicine (Baltimore), 97. 10.1097/MD.0000000000012731

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다